Special Edition: COVID-19 Call to Action

This meeting will be recorded and will be available at www.fmda.org/journalclub.php
FMDA JOURNAL CLUB
Special Edition: COVID – 19 CALL TO ACTION

Diane Sanders-Cepeda, DO  CMD
Senior Medical Director, UHC Retiree Solutions
FMDA Vice President & Journal Club Chair
Agenda

COVID SOS & Trends

Clinical Updates

Vaccination Breaking News
Total Cases: 37,138,759
28-Day Cases: 2,843,081
Total Deaths: 624,344
28-Day Deaths: 14,466
Total Vaccine Doses Administered: 357,554,226
28-Day Vaccine Doses Administered: 15,749,980
COVID-19 Weekly Situation Report: State Overview

Previous week (August 6, 2021 - August 12, 2021)

Published August 13, 2021

All data are provisional and subject to change. Data include only Florida residents.

See additional notes at the end of this report for information on positivity rate, deaths and vaccination status.

<table>
<thead>
<tr>
<th>Case data</th>
<th>Previous week</th>
<th>Cumulative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>151,415</td>
<td>2,877,214</td>
</tr>
<tr>
<td>New case positivity</td>
<td>19.3%</td>
<td>19.1%</td>
</tr>
<tr>
<td>Deaths</td>
<td>286</td>
<td>40,766</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccine data</th>
<th>Previous week</th>
<th>Cumulative</th>
</tr>
</thead>
<tbody>
<tr>
<td>People vaccinated</td>
<td>384,328</td>
<td>12,420,704</td>
</tr>
<tr>
<td>First dose</td>
<td>261,396</td>
<td>2,100,860</td>
</tr>
<tr>
<td>Series completed</td>
<td>122,932</td>
<td>10,319,844</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccine age groups</th>
<th>Population</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>19,119,043</td>
<td>65%</td>
</tr>
<tr>
<td>12-19</td>
<td>1,972,084</td>
<td>44%</td>
</tr>
<tr>
<td>20-29</td>
<td>2,744,987</td>
<td>45%</td>
</tr>
<tr>
<td>30-39</td>
<td>2,784,698</td>
<td>54%</td>
</tr>
<tr>
<td>40-49</td>
<td>2,669,253</td>
<td>63%</td>
</tr>
<tr>
<td>50-59</td>
<td>2,925,172</td>
<td>71%</td>
</tr>
<tr>
<td>60-64</td>
<td>1,438,783</td>
<td>79%</td>
</tr>
<tr>
<td>65+</td>
<td>4,584,066</td>
<td>86%</td>
</tr>
</tbody>
</table>

New cases for the past 10 weeks

Week start date

11,836  10,461  11,797  15,995  23,531  45,587  73,205  110,442  134,711  151,415
FLORIDA COVID-19 UPDATE FOR AUGUST 18, 2021

COVID-19 Hospitalizations: 16,521

COVID-19 New Cases: 23,335
National Forecasts

National Forecast

New Hospital Admissions


Bands: 95% Prediction Intervals

New Hospital Admissions


Inner Bands: 50% Prediction Intervals
Outer Bands: 95% Prediction Intervals

CDC

Reported Columbia LANIL GT-DeepCOVID MOBS JHU-APL USC Karlen

Ensemble Individual models
National Forecast

New Weekly Deaths

Total Deaths

Bands: 95% Prediction Intervals

Inner Bands: 50% Prediction Intervals

Outer Bands: 95% Prediction Intervals

Reported
Albert
B*Pagine
USA-CSE
Columbia
JHU-CSE
JHU-APL
Karlen
PSI
GT-DeepCOVID

LDNM
LSHTM
Cassandra
GHI
MIT
UCM
UCSD-NEU
UC
USC

GHI
UC
UCSD-NEU
UC
USC

Individual models

Ensemble

CDC Logo
Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Alison M. Covenagh, DPT, PhD1, 2, Kevin B. Spicer, MD, PhD3, 4, Douglas Thoroughman, PhD2, 5, Connor Glick, MS6, Kathleen Winner, PhD2, 3


<table>
<thead>
<tr>
<th>Vaccination status</th>
<th>Case-patients (No. %)</th>
<th>Control participants (No. %)</th>
<th>OR (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not vaccinated</td>
<td>179 (72.8)</td>
<td>284 (57.7)</td>
<td>2.34 (1.58–3.47)</td>
</tr>
<tr>
<td>Partially vaccinated</td>
<td>17 (6.9)</td>
<td>39 (7.9)</td>
<td>1.56 (0.81–3.01)</td>
</tr>
<tr>
<td>Fully vaccinated</td>
<td>50 (20.3)</td>
<td>169 (34.3)</td>
<td>Ref</td>
</tr>
<tr>
<td>Total</td>
<td>246 (100)</td>
<td>492 (100)</td>
<td>—</td>
</tr>
</tbody>
</table>

What is added by this report?
Among Kentucky residents infected with SARS-CoV-2 in 2020, vaccination status of those reinfected during May–June 2021 was compared with that of residents who were not reinfected. In this case-control study, being unvaccinated was associated with 2.34 times the odds of reinfection compared with being fully vaccinated.

What are the implications for public health practice?
To reduce their likelihood for future infection, all eligible persons should be offered COVID-19 vaccine, even those with previous SARS-CoV-2 infection.
Vaccines have made Covid-19 far less lethal. A fully-vaccinated 80-year-old now has the same mortality risk as an unvaccinated 50-year-old.

Risk of catching and dying from Covid* (log scale), by age group, before and after full vaccination:

- Before vaccines: Roughly 1% of all 80-year-olds in England had died from Covid.
- After two doses: A fully vaccinated 80-year-old now has roughly the same risk of dying from Covid as an unvaccinated 50-year-old.

*Risk is the population fatality rate. 
© FT
Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

United States: 5/9/2021 – 8/14/2021

WHO label Lineage # Type %Total 95%PI
Alpha B.1.1.7 VOC 0.3% 0.0-1.0%
Beta B.1.351 VOC 0.0% 0.0-0.2%
Gamma P.1 VOC 0.2% 0.0-0.7%
Delta B.1.617.2 VOC 86.1% 82.6-89.4%
AY.3 VOC 12.3% 9.1-15.7%
AY.2 VOC 0.3% 0.0-1.0%
AY.1 VOC 0.1% 0.0-0.2%
Eta B.1.525 VOI 0.0% 0.0-0.2%
Iota B.1.526 VOI 0.0% 0.0-0.2%
N/A B.1.621 0.4% 0.0-1.0%
B.1.621.1 0.1% 0.0-0.5%
B.1.628 0.1% 0.0-0.5%
A.2.5 0.0% 0.0-0.2%
B.1.626 0.0% 0.0-0.2%
B.1.617.1 VOI 0.0% 0.0-0.2%
B.1.617.3 VOI 0.0% 0.0-0.2%
Other Other* 0.0% 0.0-0.2%

* Enumerated lineages are VOI/VOC or are circulating >1% in at least one HHS region during at least one two week period; remaining lineages are aggregated as “Other”.
** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates.
# Sublineages of P.1 and B.1.351 are aggregated with the parent lineage and included in parent lineage’s proportion. AY.3 is aggregated with its parent lineage AY.3. AY.4-AY.12 aggregated with B.1.617.2

Collection date, week ending
How vaccine efficacy compares against the Alpha and Delta variants

Vaccine efficacy against infection and hospitalisation for each variant, by vaccine manufacturer, number of doses and country of study.

**Efficacy against symptomatic infection**

<table>
<thead>
<tr>
<th>Country</th>
<th>Alpha</th>
<th>Delta</th>
<th>A</th>
<th>D</th>
<th>A</th>
<th>D</th>
<th>A</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scotland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Vaccine:**
- Pfizer/BioNTech
- AstraZeneca
- Moderna

**Number of doses:**
- One
- Two

**Efficacy against hospitalisation**

<table>
<thead>
<tr>
<th>Country</th>
<th>A</th>
<th>D</th>
<th>A</th>
<th>D</th>
<th>A</th>
<th>D</th>
<th>A</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: FT research
© FT

Eli S. Rosenberg, PhD1,2; David R. Holtgrave, PhD2; Vajeera Dorabawila, PhD1; MaryBeth Conroy, MPH1; Danielle Greene, DrPH1; Emily Lutterloh, MD1,2; Bryon Backenson, MS1,2; Dina Hoefer, PhD1; Johanne Morne, MS1; Ursula Bauer, PhD1; Howard A. Zucker, MD, JD1
What about Monoclonal Antibodies Utilization?
Three outpatient mAbs have been granted EUA for the treatment of COVID-19 based on their potential to reduce progression to severe disease and hospitalization in patients at high risk:

- Post-exposure prophylaxis
  - REGEN-COV (casirivimab and imdevimab)

- Active COVID-19 infection in patients at higher risk for severe COVID-19 with mild to moderate symptoms
  - REGEN-COV (casirivimab and imdevimab)
  - Bamlanivimab/Etesevimab (currently paused\(^1\))
  - Sotrovimab (commercially available)
Covid-19-related Hospitalization or All-Cause Death* – REGEN-COV 1200 mg IV Single Dose

COVID hospitalization or all cause death:
1.0% vs. 3.2%
<table>
<thead>
<tr>
<th>Variant</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alpha (B.1.1.7)</strong></td>
<td>Susceptible to the authorized antibodies</td>
</tr>
<tr>
<td><strong>Beta (B.1.351), Gamma (P.1)</strong></td>
<td>Marked reduction in susceptibility to bam/ete (distribution paused in US) Casirivimab/imdevimab (REGEN – COV), sotrovimab expected to retain activity</td>
</tr>
<tr>
<td><strong>Delta (B.1.617.2)</strong></td>
<td>Marked reduction in susceptibility to bam; modest reduction in susceptibility to bam/ete Casirivimab/imdevimab (REGEN – COV), sotrovimab expected to have activity</td>
</tr>
</tbody>
</table>
Vaccination

Breaking News
• **August 12, 2021**: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals*
  – Other fully vaccinated individuals do not need an additional dose right now
  – Amendment applies to:
    • **Pfizer-BioNTech** COVID-19 vaccine (BNT162b2) (≥12 years old) – **Moderna** COVID-19 vaccine (mRNA-1273) (≥18 years old)
    • Due to insufficient data, the EUA amendment for an additional dose does not apply to Janssen COVID-19 vaccine or to individuals who received Janssen COVID-19 as a primary series. CDC and FDA are actively engaged to ensure that immunocompromised recipients of Janssen COVID-19 vaccine have optimal vaccine protection

Immunocompromised People

People with medical conditions or people receiving treatments that are associated with moderate to severe immune compromise.1

- Active or recent treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ or recent hematopoietic stem cell transplants
- Severe primary immunodeficiency
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids, alkylating agents, antimetabolites, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory

Additional information about the level of immune suppression associated with a range of medical conditions and treatments can be found in general best practices for vaccination of people with altered immunocompetence, the CDC Yellow Book, and the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Immunocompromised People

• **Additional Dose of mRNA COVID-19 Vaccine**
  • **Pfizer-BioNTech** COVID-19 vaccine (BNT162b2) (≥12 years old)
  • **Moderna** COVID-19 vaccine (mRNA-1273) (≥18 years old)

• Additional dose after an initial 2-dose primary series of mRNA COVID-19 vaccine, in immunocompromised people
  • **Heterologous additional dose is permitted**
  • Administered **at least 28 days** after completion of the primary mRNA COVID-19 vaccine series

Additional information about the level of immune suppression associated with a range of medical conditions and treatments can be found in general best practices for vaccination of people with altered immunocompetence, the CDC Yellow Book, and the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.
U.S. will begin wide distribution of Covid booster shots next month, saying vaccine protection wanes over time
Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

Media Statement

For Immediate Release: Wednesday, August 18, 2021

Contact: Media Relations
(404) 639-3286
Biden-Harris Administration Takes Additional Action to Protect America’s Nursing Home Residents from COVID-19
FMDA Launches COVID-19 Nursing Facility Staff Vaccination Confidence Initiative

West Palm Beach, Fla. — FMDA – The Florida Society for Post-Acute and Long-Term Care (PALTC) Medicine announces the launch of its vaccination confidence initiative focused on Florida skilled nursing facilities with the lowest staff vaccination rates. Under the auspices of FMDA’s Quality Advocacy Coalition with support from the United Health Foundation, the program aims to increase vaccination rates at skilled nursing facilities (SNF) by engaging with the staff in-person and virtually to provide knowledge, open discussion, and education through presentations and videos from world-class experts in PALTC.

FMDA is the official state affiliate and one of the largest chapters of AMDA – The Society for Post-Acute and Long-Term Care Medicine. It is also a Specialty Society of the Florida Medical Association and liaises with the Florida Osteopathic Medical Association.

“There is a lot concern and hesitancy towards the vaccine from staff in Florida’s SNFs. We want to address those concerns and provide ease of mind when it comes to getting vaccinated. It is vital to the health of our most vulnerable that we protect them,” said Leonard Hock, Chairman of the Board, FMDA.

Current data trends show a very low vaccination rate among certain nursing facilities. Florida’s Agency for Health Care Administration’s statewide data as of June 4, 2021, showed self-reported vaccination rates from 696 SNF facilities in Florida as follows: 1. 75.86 percent of SNF residents have been vaccinated, 2. 41.31 percent of SNF staff have been vaccinated, and 3. 42,330 SNF staff have been vaccinated out of a total of 102,279 statewide. This means 59,180 SNF staff have NOT been vaccinated.

“This data provides some perspective on the tough road ahead,” said FMDA President Dr. Angel Tafur. “While not totally surprising, this is very disappointing. Moreover, this is an indication of the scope and urgency of the challenge,” he added.

For more information regarding FMDA’s COVID-19 SNF Staff Vaccination Confidence Initiative, visit www.fmda.org or contact FMDA at (561) 689-6321.
Questions

Diane Sanders-Cepeda, DO CMD
diane_sanders-cepedia@uhc.com

Ian Cordes, Executive Director of FMDA
ian.cordes@fmda.org